Association between a promoter polymorphism of the paraoxonase PON1 gene and pathologically verified idiopathic Parkinson’s disease
- 1 March 2002
- journal article
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 2 (2) , 91-96
- https://doi.org/10.1046/j.1444-1586.2002.00030.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The anxiolytic effect of chronic inositol depends on the baseline level of anxietyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2000
- Gln → Arg 191 Polymorphism of Paraoxonase and Parkinson’s DiseaseHuman Heredity, 1999
- Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.Journal of Clinical Investigation, 1997
- Detection of Single-Nucleotide Polymorphisms with the WAVE™ DNA Fragment Analysis SystemGenetic Testing, 1997
- The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarinNature Genetics, 1996
- Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteinsCurrent Opinion in Lipidology, 1996
- Oxidative damage in neurodegenerative diseaseThe Lancet, 1994
- Prevalence of Movement Disorders in Elderly Community ResidentsNeuroepidemiology, 1994
- Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog SynthesisScience, 1983